Oncocin Onc112 analog a

General Information


DRACP ID  DRACP02698

Peptide Name   Oncocin Onc112 analog a

Sequence  VRKPPYLPRPRWPRrIYNr

Sequence Length  19

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
SH-SY5Y Neuroblastoma Blastoma 10% Cytotoxicity=600 µg/ml MTT assay 24 h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma 50-60% Cytotoxicity=600 µg/ml MTT assay 24 h 1
HepG2 Hepatoblastoma Blastoma <5% Cytotoxicity=600 µg/ml MTT assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HEK293: 50-60% Cytotoxicity=600 µg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  r=D-Arg

Chiral  Mix



Physicochemical Information


Formula  C105H158N32O19

Absent amino acids  ACDEFGHMQST

Common amino acids  P

Mass  249382

Pl  12.06

Basic residues  5

Acidic residues  0

Hydrophobic residues  4

Net charge  5

Boman Index  -5594

Hydrophobicity  -128.42

Aliphatic Index  56.32

Half Life 
  /

Extinction Coefficient cystines  8480

Absorbance 280nm  471.11

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 26334348

Title  Optimization of oncocin for antibacterial activity using a SPOT synthesis approach: extending the pathogen spectrum to Staphylococcus aureus

Doi 10.1007/s00726-015-2082-2

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_13596

DRACP is developed by Dr.Zheng's team.